acut
lower
respiratori
tract
infect
lrti
major
worldwid
health
problem
particularli
childhood
acut
lrti
viral
origin
influenza
respiratori
syncyti
viru
rsv
associ
greatest
diseas
burden
human
emerg
sever
acut
respiratori
syndrom
sar
coronaviru
ensu
worldwid
epidem
highlight
fact
respiratori
viral
infect
human
may
origin
anim
mani
differ
influenza
virus
occur
natur
anim
reservoir
present
constant
threat
zoonot
infect
global
pandem
influenza
virus
small
nm
diamet
contain
rna
envelop
three
type
b
c
type
classifi
accord
properti
surfac
protein
haemagglutinin
neuraminidas
subtyp
found
aquat
bird
natur
reservoir
figur
subtyp
circul
human
mammal
type
b
c
influenza
one
subtyp
restrict
human
season
ill
epidem
pandem
influenza
virus
circul
human
b
c
caus
respiratori
tract
diseas
influenza
gener
consid
clinic
sever
influenza
b
influenza
c
caus
mild
ill
confin
upper
respiratori
tract
circul
influenza
b
virus
human
figur
caus
unpredict
season
epidem
diseas
temper
climat
excess
popul
morbid
mortal
usual
occur
octob
march
northern
hemispher
last
week
uk
death
associ
influenza
b
epidem
everi
year
sever
year
widespread
pandem
sever
diseas
occur
less
frequent
occur
least
three
occas
last
centuri
associ
high
mortal
clinic
featur
influenza
b
ill
human
rang
subclin
mild
upper
respiratori
tract
symptom
sever
ill
includ
laryngotrach
pneumonia
less
commonli
death
respiratori
system
failur
common
present
symptom
cough
high
temperatur
joint
pain
gener
malais
figur
rapid
onset
short
incub
period
hour
characterist
though
incub
last
day
individu
greatest
risk
complic
preexist
cardiac
respiratori
diseas
elderli
impair
immun
system
figur
sever
ill
reflect
preexist
host
immun
prevail
viru
strain
viru
variabl
protect
immun
influenza
confer
antibodi
abil
influenza
caus
reinfect
relat
genet
mutabl
viru
everi
replic
round
mutant
virus
gener
growth
advantag
partial
evad
host
immun
respons
variant
capabl
caus
epidem
suscept
popul
emerg
process
term
antigen
drift
new
influenza
drift
variant
aris
everi
year
influenza
b
drift
variant
aris
everi
year
influenza
zoonosi
segment
natur
influenza
genom
allow
reassort
segment
singl
host
infect
one
viru
occur
regularli
aquat
bird
almost
combin
influenza
viru
segment
detect
less
common
mammal
previous
thought
novel
subtyp
influenza
aris
human
reassort
two
viru
subtyp
occur
mammal
could
transmit
human
pig
consid
suitabl
intermedi
host
avian
human
virus
differ
slightli
surfac
receptor
requir
replic
pig
howev
follow
transmiss
directli
bird
human
occas
figur
evid
crossspeci
barrier
transmiss
may
less
stringent
thought
nevertheless
requir
adapt
avian
virus
mammal
poorli
understood
crossspeci
transmiss
novel
subtyp
suscept
human
popul
antigen
shift
thought
sourc
pandem
influenza
zoonot
infect
involv
sever
differ
subtyp
influenza
occur
last
year
indic
pandem
potenti
influenza
virus
circul
domest
poultri
control
presenc
larg
mobil
anim
reservoir
influenza
viru
suggest
erad
agent
imposs
control
strategi
focu
limit
opportun
crossspeci
transmiss
novel
subtyp
exampl
hous
domest
poultri
shelter
avoid
contact
overfli
migratori
bird
eliminatingreduc
live
bird
market
hous
aquat
bird
domest
poultri
separ
slaughter
domest
flock
infect
highli
pathogen
influenza
virus
measur
may
achiev
success
prevent
zoonot
transmiss
influenza
human
littl
impact
annual
cycl
unpreced
level
circul
domest
poultri
south
east
asia
present
particularli
high
risk
emerg
novel
pandem
influenza
strain
immun
antibodi
haemagglutinin
limit
extent
neuraminidas
prevent
diseas
caus
strain
viru
basi
vaccin
influenza
current
vaccin
use
worldwid
subunit
vaccin
howev
high
variabl
influenza
viru
mean
antibodi
one
strain
confer
limit
protect
drift
variant
thu
influenza
vaccin
given
annual
influenza
season
boost
preexist
immun
composit
vaccin
updat
regularli
develop
countri
benefit
immun
led
expans
agerel
vaccin
polici
uk
vaccin
introduc
individu
year
age
irrespect
preexist
ill
vaccin
rate
vari
consider
countri
increas
interest
vaccin
children
induc
broader
longlast
immun
child
vaccin
may
also
help
prevent
transmiss
commun
gener
antivir
drug
despit
prevent
efficaci
vaccin
need
treatment
sever
influenza
remain
amantadin
relat
compound
rimantadin
recent
antiinfluenza
drug
avail
select
target
viral
protein
inhibit
viral
replic
use
limit
last
year
partli
sideeffect
dizzi
confus
particularli
affect
elderli
also
drugresist
mutant
aris
frequent
readili
transmit
neuraminidas
inhibitor
recent
develop
novel
class
antiinfluenza
compound
figur
act
viral
neuraminidas
prevent
releas
viru
particl
infect
cell
like
efficaci
given
earli
ill
sinc
uk
nation
institut
clinic
excel
recommend
neuraminidas
inhibitor
may
use
treatment
prophylaxi
certain
restrict
mutat
confer
resist
neuraminidas
inhibitor
aris
frequent
vivo
virus
contain
gener
lose
reproduct
fit
disadvantag
transmiss
suggest
widespread
resist
antivir
drug
unlik
emerg
like
treat
children
probabl
viral
load
highest
therefor
capac
viral
replic
presenc
drug
greatest
rsv
figur
negativesens
nonseg
envelop
rna
viru
nm
diamet
best
known
caus
bronchiol
infant
caus
respiratori
tract
infect
age
group
upper
respiratori
tract
infect
urti
lrti
rang
sever
subclin
infect
pneumonia
death
children
infect
rsv
first
birthday
year
age
thereaft
individu
infect
approxim
everi
year
rsv
infect
adult
probabl
underrecogn
sever
rsv
infect
elderli
may
much
underestim
caus
pneumonia
elderli
individu
thought
becom
infect
rsv
everi
year
transmiss
rsv
primarili
larg
aerosol
droplet
secret
caus
widespread
nosocomi
infect
outbreak
adult
paediatr
facil
difficult
control
rsv
infect
immunocompromis
individu
sever
lifethreaten
mortal
may
adult
bone
marrow
transplant
recipi
viral
shed
may
prolong
pathophysiolog
rsv
infect
respiratori
epithelium
lead
increas
goblet
cell
product
mucu
die
infect
ciliat
epitheli
cell
combin
mucu
form
plug
block
airway
consequ
sever
small
babi
narrow
airway
lead
characterist
sign
symptom
atelectasi
clinic
syndrom
bronchiol
rsv
bronchiti
pneumonia
peribronchiolar
interstiti
infiltr
characterist
lymphocyt
clinic
featur
sever
rsv
infect
relat
age
young
infant
ill
seldom
asymptomat
last
week
earli
sign
infect
may
includ
difficulti
feed
nasal
congest
cough
otiti
media
compat
urti
fever
often
invari
present
rsv
infect
abnorm
breath
sound
tachypnoea
hypoxaemia
suggest
lower
respiratori
tract
involv
bronchiol
pneumonia
two
primari
manifest
progress
lrti
may
difficult
distinguish
occur
simultan
clinic
featur
bronchiol
wheez
hyperaer
characterist
infant
rsv
infect
usa
rsv
estim
caus
death
per
year
children
year
age
risk
hospit
otherwis
healthi
children
admit
hospit
requir
mechan
ventil
rate
higher
first
month
may
higher
still
children
underli
acquir
congenit
cardiopulmonari
diseas
older
children
adult
rsv
infect
reinfect
usual
milder
asymptomat
respiratori
infect
lower
likelihood
lrti
adult
rsvassoci
respiratori
tract
infect
may
experi
prolong
symptom
diseas
elderli
may
particularli
sever
develop
pneumonia
investig
rsv
infect
often
diagnos
basi
clinic
featur
certainti
diagnosi
increas
rsv
known
circul
season
epidem
chest
radiographi
find
nonspecif
commonli
includ
hyperaer
peribronchi
thicken
area
consolid
interstiti
infiltr
patient
rsv
pneumonia
rang
respiratori
find
immunocompromis
adult
includ
pleural
effus
laboratori
diagnosi
depend
detect
viral
antigen
respiratori
secret
immunofluoresc
rapid
antigen
test
cultur
viru
serolog
test
littl
help
diagnosi
rsv
infect
reli
use
pair
acut
convalesc
sera
complic
prematur
young
infant
like
suffer
acut
apnoeic
episod
requir
assist
ventil
bronchiol
pneumonia
major
complic
rsv
diseas
young
children
children
congenit
heart
diseas
chronic
lung
diseas
immunocompromis
children
adult
also
risk
sever
diseas
pneumonia
major
complic
adult
elderli
estim
incid
rang
nurs
home
hospit
inpati
popul
estim
mortal
elderli
former
latter
rsv
infect
high
mortal
sever
immunocompromis
individu
manag
support
care
mainstay
manag
rsv
diseas
infanc
mainten
oxygen
hydrat
nutrit
essenti
hospit
patient
ventilatori
support
may
necessari
sever
case
trial
bronchodil
may
benefici
control
trial
corticosteroid
vitamin
supplement
prove
efficaci
infant
rsv
diseas
immun
two
subtyp
rsv
b
surfac
glycoprotein
f
g
major
antigen
viru
neutral
antibodi
direct
protect
immun
rsv
complex
antibodi
gener
natur
infect
necessarili
protect
high
proport
primari
rsv
infect
occur
month
age
matern
antibodi
level
highest
overal
current
controversi
data
suggest
neutral
antibodi
rsv
benefici
neutral
antibodi
titr
human
sera
correl
invers
likelihood
hospit
result
rsv
infect
neutral
antibodi
titr
correl
reduc
risk
reinfect
immunoglobulin
infus
high
neutral
titr
antibodi
rsv
rsvig
figur
use
treat
rsv
ill
normalrisk
highrisk
infant
normal
infant
littl
evid
justifi
rsvig
treatment
rsv
infect
howev
prophylaxi
may
use
highrisk
infant
eg
bronchopulmonari
dysplasia
assess
risk
import
intraven
rsvig
contraind
congenit
cyanot
heart
diseas
recombin
human
rsv
monoclon
antibodi
avail
intramuscular
treatment
prophylaxi
rsv
earli
clinic
data
suggest
prepar
passiv
antibodi
may
wider
applic
fewer
limit
rsvig
howev
extrem
expens
antivir
drug
avail
rsv
ribavirin
guanosin
analogu
use
wide
though
precis
mode
action
uncertain
mani
clinic
studi
show
conflict
result
sever
studi
rais
doubt
clinic
effect
ribavirin
infant
children
risk
sever
rsv
diseas
ventil
children
centr
use
restrict
immunocompromis
sever
ill
sever
rsv
vaccin
live
attenu
subunit
recombin
undergo
clinic
trial
develop
safe
vaccin
imped
poor
understand
factor
govern
immun
protect
differ
age
group
earli
vaccin
attempt
sever
diseas
seen
vaccine
like
signific
progress
futur
type
vaccin
suitabl
differ
age
group
may
differ
transmiss
sar
cov
spread
worldwid
within
week
earli
major
rout
transmiss
respiratori
primarili
droplet
secret
aerosol
format
case
result
infect
healthcar
set
emphas
import
close
contact
exposur
bodili
secret
syndrom
notic
unusu
cluster
sever
respiratori
ill
hospit
set
peak
viru
shed
day
onset
ill
figur
viru
found
variou
bodi
fluid
infecti
viru
recov
later
day
ill
onset
neutral
antibodi
detect
day
postonset
risk
factor
sar
cov
infect
close
contact
civet
catsracoon
dog
eatingprepar
civet
meat
laboratori
work
sar
cov
contact
known
case
sar
clinic
featur
present
fever
respiratori
ill
cough
short
breath
progress
acut
respiratori
distress
syndrom
death
case
fatal
increas
significantli
age
year
mortal
onset
ill
day
postinfect
mean
day
patient
suffer
later
gastrointestin
symptom
diarrhoea
vomit
manag
control
specif
control
measur
yet
develop
though
work
progress
antivir
drug
suitabl
vaccin
epidem
variou
nonspecif
therapeut
measur
use
variabl
success
corticosteroid
antimicrobi
prevent
secondari
bacteri
infect
positivepressur
ventilatori
support
antiinflammatori
drug
infus
antisera
convalesc
patient
epidem
control
mainli
public
health
measur
contacttrac
quarantin
polici
effect
littl
evid
transmiss
symptom
onset
infect
individu
easili
identifi
consid
prophylaxi
infant
year
receiv
oxygen
therapi
bronchopulmonari
dysplasia
infant
born
week
bronchopulmonari
dysplasia
like
benefit
month
prophylaxi
infant
born
week
bronchopulmonari
dysplasia
may
benefit
use
cyanot
congenit
heart
diseas
evalu
paediatr
adult
immunocompromis
patient
main
emphasi
nosocomi
outbreak
infect
control
efficaci
improv
set
initi
treatment
onset
respiratori
syncyti
viru
season
defer
live
viru
vaccin
eg
mmr
last
dose
